Kath Giles - Profile and Investment Details

Investor Profile

Kath Giles is a Venture Capital, Private Equity Firm, CEO, Investor based in Perth, Western Australia, Australia with a diverse investment portfolio that includes companies such as QUE Oncology, Elastagen, Denteric, MecRx, Spinifex Pharmaceuticals, Curtin University, Heart Metabolics, Spark Co Lab, PolyActiva, Cardiora, Q-Sera, Okogen, Ena Respiratory, G I Therapies, Cerulean Medical, Protego Medical, Vaxxas, Myricx Pharma, Signostics, EBR Systems, Auspherix, Solvanix, MetaBloQ, Dimerix, OccuRx, Global Kinetics Corporation, Aravax, Fibrotech Therapeutics, . Over time, Kath Giles has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Kath Giles is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Life Science, Education, Biotechnology, Health and Hospital Services, Neuroscience, Health Diagnostics, Medical, Therapeutics, Media and Entertainment, Pharmaceuticals may find it worthwhile to explore potential connections with Kath Giles, as their portfolio suggests a familiarity and interest in this area.

Understanding Kath Giles’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.